CtrlK
A surgical robot is a computer-controlled robotic system used to assist surgeons during medical procedures. These systems translate a surgeon's hand movements into precise, scaled motions of miniaturized instruments inside the patient's body, enabling minimally invasive surgery with enhanced dexterity, visualization, and control. Since the early 1990s, surgical robots have transformed operating rooms across dozens of specialties, from urology and gynecology to orthopedics and cardiac surgery.
The field is dominated by the da Vinci Surgical System made by Intuitive Surgical, which held a near-monopoly on soft-tissue surgical robotics for over two decades. As of December 2025, over 11,100 da Vinci systems were installed worldwide and had been used in more than 20 million procedures. A growing number of competitors, including Medtronic's Hugo RAS, Stryker's Mako, and Johnson & Johnson's Ottava, are entering the market as the global surgical robotics industry surpasses $12 billion in annual revenue.
The origins of surgical robotics trace back to the mid-1980s. In 1985, the PUMA 560 robotic arm was used to place a needle for a brain biopsy under CT guidance at Memorial Medical Center in Long Beach, California, marking one of the earliest uses of a robot in a surgical setting. While the PUMA 560 was an industrial robot adapted for medical use, it demonstrated that robotic precision could benefit operative procedures.
Research and development for ROBODOC began in 1986 when IBM's Thomas J. Watson Research Center and researchers at the University of California, Davis started a collaborative initiative focused on total hip arthroplasty. The effort was led by Howard "Hap" Paul, a doctor of veterinary medicine, and William Bargar, an orthopedic surgeon. By 1990, the system had been used to perform a total hip replacement on a dog. On November 7, 1992, a surgical team led by Bargar at Sutter General Hospital in Sacramento, California used ROBODOC to perform the first robot-assisted human hip replacement. The robot used preoperative data from CT scans to plan the optimal cavity for a hip implant and then milled the femoral canal with sub-millimeter accuracy. Laboratory testing showed that ROBODOC created cavities in which 95% of the implant surface was within 1 mm of bone. The success of this initial procedure cleared the way for nationwide clinical trials beginning in 1993. ROBODOC was developed commercially by Integrated Surgical Systems, a company cofounded by Paul and Bargar, and received FDA approval in 1998. It was subsequently used in more than 28,000 procedures worldwide before Integrated Surgical Systems closed in 2005.
In 1994, the Automated Endoscopic System for Optimal Positioning (AESOP), developed by Computer Motion under a Small Business Innovation Research contract from NASA's Jet Propulsion Laboratory, received FDA clearance. AESOP became the first robot approved by the FDA to assist in surgery. Its function was to maneuver an endoscope inside the patient's body based on voice commands given by the surgeon, freeing a human assistant from the task of holding the camera. AESOP was the first voice-controlled robot to receive FDA clearance and represented a key proof of concept for robotic surgical assistance.
Building on the AESOP platform, Computer Motion developed the ZEUS Surgical System. A first prototype was demonstrated in 1995 and tested on animals in 1996. In 1998, ZEUS carried out its first tubal re-anastomosis procedure and its first coronary artery bypass graft (CABG) procedure. The system was introduced commercially in 1998 and pioneered the concept of telepresence surgery, in which the surgeon sits at a console separated from the patient cart and controls robotic arms remotely.
By 2000, ZEUS was equipped to hold 28 different surgical instruments. In 2001, the system achieved a historic milestone when it was used by Jacques Marescaux and Michel Gagner to perform the "Lindbergh Operation," a cholecystectomy (gallbladder removal) on a patient in Strasbourg, France, while the surgeon operated from New York City, over 6,000 kilometers away. ZEUS received FDA clearance in 2001.
However, on March 7, 2003, Computer Motion and Intuitive Surgical merged. Following the merger, the ZEUS system was phased out in favor of Intuitive Surgical's da Vinci system, which had already gained significant market traction.
The da Vinci Surgical System is the most commercially successful surgical robot in history. It was developed by Intuitive Surgical, a company founded in 1995 in Sunnyvale, California. The technology originated in part from research funded by the Defense Advanced Research Projects Agency (DARPA) in the late 1980s, which aimed to enable surgeons to operate on wounded soldiers remotely via telepresence.
The original da Vinci system received FDA clearance in 1997 for surgical assistance and in July 2000 for performing laparoscopic surgery. The 2000 clearance covered adult and pediatric use in urologic, general laparoscopic, gynecologic, non-cardiovascular thoracoscopic, and thoracoscopically assisted cardiotomy procedures. The system became commercially available in the United States in 2000.
Intuitive Surgical has released multiple generations of the da Vinci platform:
| Generation | Model | Year Introduced | Key Features |
|---|---|---|---|
| 1st | da Vinci Classic | 2000 | Three robotic arms (later four), 3D visualization, EndoWrist instruments |
| 2nd | da Vinci S | 2006 | 3D high-definition camera, simplified setup, interactive touchscreen display |
| 3rd | da Vinci Si | 2009 | Dual-console capability for training, fluorescence imaging, system intelligence moved to vision cart |
| Budget | da Vinci X | 2017 | Hybrid of Si patient cart with Xi instruments, lower cost option |
| 4th | da Vinci Xi | 2014 | Overhead boom-mounted arms, thinner arms for multi-quadrant surgery, integrated table motion |
| Single Port | da Vinci SP | 2018 | All instruments through a single 2.5 cm cannula, designed for confined anatomical spaces |
| 5th | da Vinci 5 | 2024 | Force feedback, 10,000x computing power of Xi, 150+ enhancements, smaller footprint |
The fifth-generation da Vinci 5 received FDA clearance in March 2024 and CE mark approval in Europe in 2025. It features force feedback technology that allows surgeons to feel subtle forces exerted on tissue during surgery. In preclinical trials, this force feedback demonstrated up to 43% less force exerted on tissue, potentially reducing trauma. The da Vinci 5 also includes 10,000 times the computing power of the da Vinci Xi, integrated insufflation and electrosurgical units, and a redesigned surgeon console with customizable positioning.
The da Vinci Surgical System consists of three main components: the surgeon console, the patient-side cart, and the vision system.
Surgeon Console. The surgeon sits at an ergonomic console, typically located several feet from the operating table. Looking through a stereoscopic viewer, the surgeon sees a magnified, high-definition 3D image of the surgical field. Two hand controllers (called masters) and foot pedals allow the surgeon to control the robotic arms and instruments. The console translates the surgeon's hand, wrist, and finger movements into corresponding movements of the instruments at the patient side in real time.
Patient-Side Cart. The patient cart holds up to four robotic arms that extend over the patient on the operating table. Three arms carry interchangeable surgical instruments, while a fourth holds the endoscopic camera. The arms are introduced into the body through small incisions (typically 1 to 2 cm) via cannulas, also called trocars.
Vision System. The camera arm contains two optical channels within a single metallic sheath, mimicking binocular vision. This provides the surgeon with a stereoscopic 3D view magnified up to 10 times. A vision cart houses the image processing hardware and connects all system components, facilitating communication between the surgeon console and the patient cart.
EndoWrist Instruments. A defining feature of the da Vinci system is its EndoWrist technology. These are miniaturized, wristed instruments mounted on the robotic arms that provide seven degrees of freedom, exceeding the range of motion of the human wrist. The instruments include graspers, scissors, needle drivers, electrocautery tools, and specialized devices for specific procedures. Built-in motion-scaling software translates large hand movements into micro-movements at the instrument tip, while tremor-filtering algorithms eliminate the natural tremor of the surgeon's hands by sampling hand position approximately 1,500 times per second.
The da Vinci platform has experienced sustained global growth:
| Year | Installed Systems | Annual Procedures |
|---|---|---|
| 2005 | ~500 | ~50,000 |
| 2010 | ~1,750 | ~278,000 |
| 2015 | ~3,600 | ~652,000 |
| 2020 | ~5,989 | ~1,243,000 |
| 2024 | ~9,902 | ~2,683,000 |
| 2025 | ~11,106 | ~3,200,000 |
As of December 2025, Intuitive Surgical reported an installed base of 11,106 da Vinci systems worldwide and had placed 1,721 systems during the year, including 870 da Vinci 5 units. The company announced in 2025 that over 20 million patients had benefited from da Vinci surgery globally. Intuitive projects that worldwide da Vinci procedures will increase approximately 13% to 15% in 2026 compared to 2025.
Surgical robots provide several advantages over traditional open surgery and conventional laparoscopic surgery:
Enhanced Precision and Dexterity. Robotic arms can rotate 360 degrees and replicate natural hand movements with significantly reduced tremor. The EndoWrist instruments provide seven degrees of freedom in confined spaces, allowing surgeons to perform delicate maneuvers that would be difficult or impossible with rigid laparoscopic instruments.
Superior 3D Visualization. Robotic systems offer high-definition, stereoscopic 3D visualization of the surgical field, providing depth perception and spatial awareness that surpass traditional 2D laparoscopic views. Magnification of 10x or more allows surgeons to identify fine anatomical structures, particularly in delicate regions such as the pelvis and abdomen.
Tremor Filtering and Motion Scaling. Position sensing at approximately 1,500 cycles per second effectively eliminates involuntary hand tremors. Motion scaling allows surgeons to map large hand movements to micro-scale instrument movements, which is particularly valuable in microsurgery and procedures requiring sub-millimeter accuracy.
Smaller Incisions and Faster Recovery. Because robotic instruments enter the body through incisions as small as 1 cm, patients typically experience less blood loss, less postoperative pain, shorter hospital stays, and faster return to normal activities compared to open surgery.
Ergonomic Benefits for Surgeons. The seated console position reduces physical fatigue during long procedures. Surgeons report less neck, back, and shoulder strain compared to standing at the operating table for extended periods during open or conventional laparoscopic surgery.
Medtronic launched the Hugo Robotic-Assisted Surgery (RAS) system, receiving CE mark approval in Europe in 2021. Hugo features a modular design with independent, mobile robotic arms that can be individually positioned around the operating table, unlike the da Vinci's unified patient cart. The system received FDA clearance for urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy, in December 2025. As of that date, Hugo was available in more than 30 countries and had been used in tens of thousands of procedures in urology, gynecology, and general surgery. Medtronic intends to expand Hugo's U.S. indications to general and gynecologic surgical procedures over time.
Stryker's Mako SmartRobotics platform is the leading robotic system for orthopedic joint replacement. Originally developed by MAKO Surgical Corp. (founded in 2004, acquired by Stryker in 2013 for $1.65 billion), Mako combines 3D CT-based preoperative planning with AccuStop haptic technology that provides tactile boundaries during bone preparation. The system is used for total knee arthroplasty, total hip arthroplasty, and partial knee arthroplasty.
As of 2025, the Mako installed base surpassed 3,000 systems worldwide across 45 countries, with more than 1.5 million procedures performed. Stryker has also expanded Mako's indications to include robotic-arm-assisted reverse total shoulder arthroplasty.
Johnson & Johnson MedTech is developing the Ottava robotic surgical system, which takes a distinctive approach by integrating robotic arms directly into the operating table rather than using a separate patient-side cart. This design aims to reduce clutter in the operating room and simplify setup. The first cases in the Ottava investigational device exemption (IDE) clinical study were completed in early 2025 at Memorial Hermann-Texas Medical Center. In January 2026, Johnson & Johnson submitted Ottava to the FDA through the De Novo classification pathway, seeking authorization for multiple procedures in general surgery within the upper abdomen, including gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair. The company also received IDE approval in late 2025 to begin a U.S. clinical trial for Ottava in inguinal hernia procedures. Ottava has not yet received marketing authorization in any market.
CMR Surgical, based in Cambridge, England, developed the Versius surgical robot as a compact, modular alternative to the da Vinci system. Each robotic arm is an independent, mobile unit that can be positioned freely around the patient, and the system is designed to fit into existing operating rooms without major infrastructure changes. The original Versius received FDA clearance through the De Novo pathway in October 2024, and the next-generation Versius Plus received 510(k) clearance in December 2025 for cholecystectomy (gallbladder removal). Outside the U.S., the system has been used in more than 40,000 procedures across over 30 countries in Europe, Asia, the Middle East, Africa, and Latin America, making it the second most widely used soft-tissue surgical robot globally. CMR plans to begin launching Versius Plus in the U.S. in 2026.
The Senhance Surgical System, originally developed by Asensus Surgical, takes a different approach by enhancing traditional laparoscopy rather than replacing it. The system is notable for being the first surgical robot to offer haptic feedback, transmitting forces sensed by the robotic instruments to the surgeon's hands. It also features eye-tracking camera control, allowing the surgeon to move the endoscopic camera with natural eye movements, and offers the smallest robotic instruments available at 3 mm diameter.
Senhance is FDA-cleared for general, gynecologic, colorectal, and pediatric surgery. In August 2024, Karl Storz, the German endoscope manufacturer, completed its acquisition of Asensus Surgical. Karl Storz is continuing development of the next-generation LUNA system, which combines Asensus's robotic surgery platform with Karl Storz's visualization capabilities.
| System | Company | Specialty | Regulatory Status (as of early 2026) |
|---|---|---|---|
| ROSA Knee / ROSA Hip | Zimmer Biomet | Orthopedic joint replacement | FDA cleared |
| Ion | Intuitive Surgical | Robotic-assisted bronchoscopy for lung biopsy | FDA cleared (2019) |
| Monarch | Johnson & Johnson (Auris Health) | Robotic-assisted bronchoscopy and endoscopy | FDA cleared (2018) |
| VELYS | Johnson & Johnson (DePuy Synthes) | Robotic-assisted total knee replacement | FDA cleared (2021) |
| Mazor X Stealth | Medtronic | Spine surgery | FDA cleared |
| ExcelsiusGPS | Globus Medical | Spine surgery | FDA cleared |
| CorPath GRX | Siemens Healthineers (Corindus) | Vascular / interventional cardiology | FDA cleared |
| Feature | da Vinci Xi (Intuitive) | da Vinci 5 (Intuitive) | Hugo RAS (Medtronic) | Versius (CMR Surgical) | Senhance (Karl Storz) |
|---|---|---|---|---|---|
| Year Introduced | 2014 | 2024 | 2021 (CE mark) | 2020 (CE mark) | 2017 (CE mark) |
| Robotic Arms | 4 (unified cart) | 4 (unified cart) | 4 (modular, independent) | Up to 4 (modular, independent) | Up to 4 (modular, independent) |
| Haptic Feedback | No | Yes (Force Feedback) | No | No | Yes |
| 3D Visualization | Yes (HD) | Yes (enhanced) | Yes (HD) | Yes (HD) | Yes (HD) |
| Eye Tracking | No | No | No | No | Yes |
| Console Type | Closed, immersive | Closed, immersive (redesigned) | Open | Open | Open |
| Instrument Articulation | EndoWrist (7 DOF) | EndoWrist (7 DOF) | Articulating (7 DOF) | Wristed (7 DOF) | Articulating |
| FDA Cleared | Yes | Yes (2024) | Yes (Dec 2025, urology) | Yes (Oct 2024; Plus Dec 2025) | Yes |
| Estimated System Cost | $1.5M to $2.5M | Not publicly disclosed | ~$1M to $2M (estimated) | ~$1M (estimated) | ~$0.5M to $1M (estimated) |
The integration of artificial intelligence into surgical robots represents the next frontier in the field. While current commercial systems are surgeon-controlled (the robot does not make autonomous decisions), AI is being incorporated in several ways.
AI-powered computer vision systems can analyze the surgical field in real time, identifying anatomical structures, highlighting critical landmarks such as blood vessels and nerves, and providing visual overlays to guide the surgeon. These systems use deep learning models trained on large datasets of annotated surgical video. Intuitive Surgical has invested in this area, and its da Vinci 5 platform includes significantly enhanced computing power (10,000 times that of the Xi) to support AI-driven software applications.
AI algorithms can automatically recognize which phase of a procedure is currently being performed by analyzing video feeds from the endoscopic camera. This capability enables automated surgical workflow documentation, real-time decision support (alerting the team to expected next steps), and postoperative analytics. Research published in leading journals has demonstrated that convolutional neural networks and transformer models can achieve high accuracy in recognizing surgical phases across multiple procedure types.
Research into autonomous surgical robots has made significant progress. In January 2022, the Smart Tissue Autonomous Robot (STAR), developed by Axel Krieger and colleagues at Johns Hopkins University, performed laparoscopic intestinal anastomosis (reconnecting two ends of the intestine) on a live pig without direct human control of the instruments. The robot used machine learning algorithms combined with a specialized imaging system to plan and execute suture placement with 83% accuracy, matching or exceeding the performance of expert human surgeons on the same task. The results were published in Science Robotics.
In 2025, a hierarchical surgical robot transformer (SRT-H) developed at Johns Hopkins demonstrated the ability to perform a complete gallbladder removal procedure comprising 17 surgical tasks, learned by watching videos of surgeons. The system achieved 100% task completion accuracy in testing.
Despite these advances, fully autonomous surgical robots remain in the research stage. Current clinical practice requires a trained surgeon to be in control at all times. The path from supervised autonomy to fully autonomous operation will require extensive validation, regulatory frameworks for autonomous medical devices, and resolution of complex liability and ethical questions.
AI is also being applied to surgical education and skills assessment. Machine learning models can analyze a trainee's instrument movements, economy of motion, and task completion metrics to provide objective performance feedback. Intuitive Surgical's dual-console da Vinci Si and Xi systems already support proctored training, and AI-based analytics are being integrated to accelerate the learning curve for new robotic surgeons.
The global surgical robotics market has grown rapidly and is projected to continue expanding. Multiple market research firms estimated the market at approximately $12.5 billion to $13.8 billion in 2025, with projections reaching $27 billion by 2030 (at a compound annual growth rate of roughly 14% to 17%).
| Year | Estimated Global Market Size |
|---|---|
| 2020 | ~$5.5 billion |
| 2023 | ~$8.5 billion |
| 2025 | ~$12.5 to $13.8 billion |
| 2026 (projected) | ~$14.5 to $16.1 billion |
| 2030 (projected) | ~$27 billion |
Sources: MarketsandMarkets, Grand View Research, Precedence Research (estimates vary by firm and methodology).
Intuitive Surgical dominates the market, with 2025 revenues exceeding $8 billion. The company's revenue model includes system placements (capital sales and operating leases), recurring instrument and accessory sales (which constitute the largest revenue segment), and service contracts.
The cost of acquiring and operating a surgical robot remains a significant barrier to adoption, particularly for smaller hospitals and healthcare systems in developing countries. A da Vinci Xi system costs approximately $1.5 million to $2.5 million, depending on configuration and accessories. Annual maintenance contracts typically run $120,000 to $240,000. Per-procedure instrument costs can exceed $2,000 due to the proprietary, limited-use instruments that must be replaced after a set number of uses. These costs mean that robotic procedures are often more expensive than conventional laparoscopic procedures, and demonstrating a clear return on investment requires high procedure volumes.
Learning to operate a surgical robot requires dedicated training. Surgeons typically undergo a structured program that includes online didactic modules, hands-on simulation practice, cadaver or animal lab training, and proctored clinical cases with an experienced robotic surgeon. The initial training and implementation process for a new da Vinci program commonly spans several weeks, with associated costs of $20,000 to $60,000 per surgeon. Achieving proficiency in complex robotic procedures may require 20 to 50 cases depending on the procedure type and the surgeon's prior laparoscopic experience.
Until the introduction of the da Vinci 5 in 2024, the dominant surgical robot on the market lacked haptic (force) feedback. Surgeons using earlier da Vinci models rely entirely on visual cues to gauge tissue tension and instrument forces, which can increase the risk of inadvertent tissue damage, particularly among less experienced operators. The Senhance system offered haptic feedback, but it had limited market penetration. The inclusion of force feedback in the da Vinci 5 addresses this long-standing criticism.
Surgical robots are large devices that require dedicated operating room space. Docking the patient cart and calibrating instruments adds setup time compared to conventional surgery. While newer systems such as Hugo RAS and Versius have addressed this with modular, independently mobile arms, the footprint of robotic equipment remains a practical concern for many hospitals.
As AI capabilities expand and research progresses toward greater surgical autonomy, regulators face new challenges in establishing safety standards and approval pathways for intelligent surgical systems. Questions about liability in the event of a malfunction or adverse outcome during robot-assisted surgery remain an active area of legal and ethical debate.
Surgical robots are used across a wide range of medical specialties:
| Specialty | Common Robotic Procedures |
|---|---|
| Urology | Radical prostatectomy, nephrectomy, cystectomy, pyeloplasty |
| Gynecology | Hysterectomy, myomectomy, sacrocolpopexy, endometriosis excision |
| General Surgery | Cholecystectomy, hernia repair, bariatric surgery (gastric bypass, sleeve gastrectomy), colorectal resection |
| Cardiac Surgery | Mitral valve repair, coronary artery bypass, atrial septal defect closure |
| Thoracic Surgery | Lobectomy, thymectomy, mediastinal mass resection |
| Head and Neck Surgery | Transoral robotic surgery (TORS) for oropharyngeal tumors |
| Orthopedics | Total knee arthroplasty, total hip arthroplasty, partial knee arthroplasty, shoulder arthroplasty |
| Spine Surgery | Pedicle screw placement, spinal fusion |
| Pulmonology | Robotic bronchoscopy for lung biopsy (Ion, Monarch) |
Radical prostatectomy remains the single most common robotic procedure worldwide. In the United States, more than 85% of prostatectomies are now performed robotically.
Several trends are shaping the future of surgical robotics: